Octave Specialty Group: Third Quarter 2026 Earnings Call - OCTAVE SPECIALTY GROUP INC

Explicit Guidance:

• FY2026 Adjusted Net Income: Confirmed expectation to deliver positive adjusted net income per share for the first time since the 2021 P&C strategy launch, meeting or exceeding prior guidance.
• Insurance Distribution Adjusted EBITDA (FY2026): Expected to exceed the $45 million guidance, driven by organic growth and ArmadaCare contribution.
• Insurance Distribution Organic Growth (FY2026): Confirmed on track to exceed full-year guidance of 25%+ (actual YTD growth >35%); expects double-digit organic growth in Q4 2026.
• Everspan Adjusted EBITDA (FY2026): Expected to meet or beat the $6 million guidance.
• Everspan Gross Premiums Written (FY2026): Full-year total likely to come in slightly under the $410 million guidance due to business mix shifts and new program launch timing.
• Corporate Adjusted Expenses (FY2026): Full-year target maintained at approximately $29.5 million (YTD YTD adjusted expenses were $22.5 million).
• FY2028 Consolidated Adjusted EBITDA: Target of $80 million to shareholders maintained.

Business-Segment Outlook:

• Insurance Distribution:
  • Growth Drivers: Future organic growth to be supported by bolt-on team launches (alternative to startups) and launching adjacent products within existing platforms; seven product adjacencies launched YTD in the U.S.
  • Capacity: 2027 capacity largely lined up and expected to be oversubscribed.
  • MGA Pipeline: Strong pipeline of startup MGA opportunities in the U.S. and Europe; expectation to integrate one or two new teams in late 2026/2027 with continued high selectivity.
  • A&H Segment: Expected to continue delivering double-digit rate increases due to healthcare cost surges; strong early momentum heading into January 1 renewals; serves as a buffer against P&C headwinds.
  • DeNovo MGAs: Currently a drag on EBITDA (-$1.2M in Q3); expected to transition to EBITDA contributors as they hit scale in coming quarters.
• Everspan (Specialty P&C):
  • Portfolio Mix: Continuing diversification into package and non-CAT property business to complement the casualty book for more balanced underwriting results.
  • Premium Growth: New programs added in Q3 expected to support premium growth in Q4, potentially performing in line to better than Q3, though ramp-up timing is variable.
  • Profitability: Expected to improve to a consistent attractive combined ratio; YTD combined ratio improved to 96.7% (pro forma).
  • Transaction Impact: Sale of Providence Washington Insurance Company (T-WIC) expected to close by early 2027, releasing capital, eliminating regulatory costs, and increasing tangible book value by ~$11 million.
• Corporate/Operations:
  • Cost Reduction: Exploring further savings initiatives for 2027 via global integration; initial phase of target operating model for international operations planned for later in the year.

Market and Competitive Outlook:

• P&C Market Dynamics: Global commercial rates expected to remain under pressure with decline for a ninth consecutive quarter driven by abundant capacity; property rates fell ~10% in Q3.
• Rate Trends: Rates held better in large casualty and alternative classes; Energy market remains cautious due to compounding rate reductions and elevated losses; Casualty SME classes (general liability, specialty) seeing double-digit rate increases.
• Competition: Market remains competitive with robust competition in large casualty; new entrants (foreign carriers, ILS capital) continue to move capital into the E&S market.
• Pricing Environment: Most classes softening from a position of strength; rate adequacy remains strong across managed portfolios.
• AI Disruption: Management maintains that AI will increase MGA productivity and serve as a competitive differentiator for complex specialty risks, not disintermediate them; rollout of AI-driven intake across US MGAs largely complete.

Macro / Industry Outlook:

• P&C Cycle: Broad expectation of continued softening in U.S. and global P&C markets through the cycle, with Property absorbing the most pressure.
• A&H Cycle: Distinct from P&C cycle; expected to continue trending upward with favorable pricing due to structural healthcare cost increases.
• Regulatory/Legal: Social inflation and federal regulations continue to drive loss outcomes in the Commercial Auto segment; management believes the "21 and 22" accident year books are effectively closed out, with 2023/2024 books running down.

Strategic Initiatives:

• M&A Strategy: Focus remains on organic growth via "bolt-on" teams and adjacent product launches; no expectation of major acquisitions, though modest "tuck-in" opportunities may be explored if a moderate size opportunity arises.
• Buy-Ins: Priority shift toward buying minority interests (NCI) in existing MGA partners to enhance bottom-line earnings without impacting top-line revenue significantly.
• Technology Integration: Enterprise underwriting platform utilizing AI to create bespoke tools for each MGA niche; goal to improve operating leverage and underwriting velocity.
• Capital Deployment: Net leverage ratio fell below 3.0x at Sept 30, 2026, providing flexibility for strategic initiatives including NCI buy-ins and non-core asset sales.

Risks and Headwinds to Outlook:

• Everspan Guidance: Full-year Gross Premiums Written may fall short of $410 million guidance due to mix shifts and timing of new program ramps.
• Commercial Auto Development: Reserves remain subject to social inflation and regulatory impacts; while "clipping the tail" is in progress, residual development may occur from 2023/2024 books.
• Market Conditions: Continued softening in P&C rates could pressure pricing in specific lines if market dynamics shift unexpectedly.
• AI Execution: Reliance on AI-driven platforms for integration and efficiency; failure to realize productivity gains could impact operating leverage.
• Integration Costs: Ongoing global integration and target operating model implementation carry execution risk and potential timing delays.

Management Tone on the Future:

• Confidence Level: Increasingly confident in Octave's trajectory; described 2026 as a meaningful milestone year for profitability.
• Strategic Clarity: Priorities remain clear: execute with discipline, capitalize on platform strengths, and deliver sustained profitable growth.
• Valuation View: Believes fundamental value is not yet fully reflected in market valuation; management feels the company is "well positioned" for 2027.
• Guidance Updates: No update to FY2026 guidance provided, but firm confidence in meeting or exceeding all key metrics.